Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Revenues
Total revenues	$ 696,644	$ 501,830
Cost and expenses
Research and development	210,702	129,078
Selling, general and administrative	327,938	266,864
Amortization of acquired intangible assets	7,100	300
Total cost and expenses	790,160	581,007
Loss from operations	(93,516)	(79,177)
Interest expense	(892)	(1,005)
Interest and other income, net	9,600	13,419
Loss before income taxes	(84,808)	(66,763)
Income tax expense	(283)	(173)
Net loss	(85,091)	(66,936)
Unrealized gain on available-for-sale securities, net of tax and foreign currency translation adjustment	56	147
Comprehensive loss	$ (85,035)	$ (66,789)
Net loss per share (Note 14):
Basic (in dollars per share)	$ (0.60)	$ (0.50)
Diluted (in dollars per share)	$ (0.60)	$ (0.50)
Weighted-average number of shares used in computing basic and diluted net loss per share:
Basic (in shares)	141,502	134,750
Diluted (in shares)	141,502	134,750
Foresight Diagnostics, Inc.
Cost and expenses
Amortization of acquired intangible assets	$ 5,709	$ 0
Product revenues
Revenues
Total revenues	693,868	500,036
Cost and expenses
Cost of revenues	245,203	184,613
Licensing and other revenues
Revenues
Total revenues	2,776	1,794
Cost and expenses
Cost of revenues	$ 608	$ 452